
No results matched your search
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
Technical Indicators | Sell | Neutral | Strong Sell | Strong Sell | BUY |
Summary | Strong Sell | Sell | Strong Sell | Strong Sell | Neutral |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bearish | 30 | Current | |||
Deliberation Bearish | 1H | Current | |||
Doji Star Bearish | 1H | Current | |||
Completed Patterns | |||||
Engulfing Bearish | 1W | 2 | Feb 14, 2021 | ||
Evening Doji Star | 1W | 2 | Feb 14, 2021 | ||
Engulfing Bearish | 15 | 2 | Mar 05, 2021 21:15 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NASDAQ | 1.3700 | 1.3500 | 1.4200 | 410,755 | -3.52% | USD | 05/03 | ||
Sydney | 0.030 | 0.030 | 0.031 | 3,259,103 | 0.00% | AUD | 03:37:43 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Zenith Bank | 25.30 | 25.40 | 24.95 | 0.00 | 0.00% | 46.85M | 05/03 | ||
FBN Holdings | 7.10 | 7.10 | 6.85 | +0.05 | +0.71% | 26.50M | 05/03 | ||
Guaranty Trust Bank | 31.20 | 31.05 | 30.90 | -0.50 | -1.59% | 20.83M | 05/03 | ||
UBA | 7.95 | 7.95 | 7.85 | 0.00 | 0.00% | 23.30M | 05/03 | ||
MTN Nigeria | 160.20 | 160.20 | 160.20 | -9.80 | -5.76% | 643.20K | 05/03 | ||
Oando Plc | 2.65 | 3.00 | 2.65 | -0.25 | -8.62% | 4.05M | 05/03 | ||
Access Bank | 7.90 | 7.85 | 7.70 | +0.10 | +1.28% | 10.47M | 05/03 | ||
Fidson | 4.650 | 4.650 | 4.650 | +0.240 | +5.44% | 162.29K | 05/03 | ||
Japaul Gold Ventures | 0.51 | 0.50 | 0.48 | -0.04 | -7.55% | 12.46M | 05/03 | ||
Julius Berger | 18.70 | 18.80 | 18.80 | +0.10 | +0.53% | 329.30K | 05/03 |
Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review